CRP and hypertensive disorder: treatment was discontinued in three patients due to adverse events (hypertension; bone marrow depression; pancytopenia with hemolytic anemia) and in four patients due to serious adverse events (dialysis; sepsis with pneumonia, hemodialysis and renal failure; hypertension with angina pectoris; decreased hemoglobin with increased CRP).